These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 22278138)
61. Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Monti C; Derosa G Expert Opin Pharmacother; 2011 Jun; 12(9):1351-8. PubMed ID: 21510830 [TBL] [Abstract][Full Text] [Related]
62. Managing cardiovascular and renal risk: the potential of direct renin inhibition. Sever PS; Gradman AH; Azizi M J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253 [TBL] [Abstract][Full Text] [Related]
63. Aliskiren: a new drug for an old problem. Barrios V; Escobar C Cardiovasc Hematol Agents Med Chem; 2010 Jan; 8(1):1-10. PubMed ID: 20210772 [TBL] [Abstract][Full Text] [Related]
64. Aliskiren, a direct renin inhibitor, improves vascular endothelial function in patients on hemodialysis independent of antihypertensive effect ∼ a pilot study∼. Moriya H; Kobayashi S; Ohtake T; Tutumi D; Mochida Y; Ishioka K; Oka M; Maesato K; Hidaka S; Nomura S Kidney Blood Press Res; 2013; 37(2-3):190-8. PubMed ID: 23736778 [TBL] [Abstract][Full Text] [Related]
65. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease. Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Małgorzewicz S; Rutkowski B Am J Hypertens; 2012 Jun; 25(6):636-9. PubMed ID: 22357413 [TBL] [Abstract][Full Text] [Related]
66. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Vaidyanathan S; Jarugula V; Dieterich HA; Howard D; Dole WP Clin Pharmacokinet; 2008; 47(8):515-31. PubMed ID: 18611061 [TBL] [Abstract][Full Text] [Related]
67. Aliskiren/amlodipine combination for the treatment of hypertension. Billecke SS; Marcovitz PA Drugs Today (Barc); 2011 Jun; 47(6):403-17. PubMed ID: 21695283 [TBL] [Abstract][Full Text] [Related]
68. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren. Ichihara A; Sakoda M; Kurauchi-Mito A; Narita T; Kinouchi K; Bokuda K; Itoh H J Pharmacol Sci; 2010; 113(4):296-300. PubMed ID: 20675959 [TBL] [Abstract][Full Text] [Related]
69. Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension. Guo JQ; Wang HY; Sun NL Chin Med J (Engl); 2013 Apr; 126(7):1242-6. PubMed ID: 23557551 [TBL] [Abstract][Full Text] [Related]
70. How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders? Jagadeesh G; Balakumar P; Stockbridge N Cell Signal; 2012 Aug; 24(8):1583-91. PubMed ID: 22522051 [TBL] [Abstract][Full Text] [Related]
71. Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Kuriyama S; Yokoyama K; Hara Y; Sugano N; Yokoo T; Hosoya T Clin Exp Nephrol; 2014 Oct; 18(5):821-30. PubMed ID: 24253615 [TBL] [Abstract][Full Text] [Related]
72. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Sullivan JE; Keefe D; Zhou Y; Satlin L; Fang H; Yan JH Clin Pediatr (Phila); 2013 Jul; 52(7):599-607. PubMed ID: 23610239 [TBL] [Abstract][Full Text] [Related]
73. Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension. Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Mizuno K Ren Fail; 2012; 34(4):442-7. PubMed ID: 22260457 [TBL] [Abstract][Full Text] [Related]
75. Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. Lange S; Fraune C; Alenina N; Bader M; Danser AH; Frenay AR; van Goor H; Stahl R; Nguyen G; Schwedhelm E; Wenzel UO J Hypertens; 2013 Apr; 31(4):713-9. PubMed ID: 23407438 [TBL] [Abstract][Full Text] [Related]
76. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124 [TBL] [Abstract][Full Text] [Related]
77. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976 [TBL] [Abstract][Full Text] [Related]
78. Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients. De Ciuceis C; Savoia C; Arrabito E; Porteri E; Mazza M; Rossini C; Duse S; Semeraro F; Agabiti Rosei C; Alonzo A; Sada L; La Boria E; Sarkar A; Petroboni B; Mercantini P; Volpe M; Rizzoni D; Agabiti Rosei E Hypertension; 2014 Oct; 64(4):717-24. PubMed ID: 24980672 [TBL] [Abstract][Full Text] [Related]
79. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Stucchi P; Cano V; Ruiz-Gayo M; Fernández-Alfonso MS Br J Pharmacol; 2009 Oct; 158(3):771-8. PubMed ID: 19694726 [TBL] [Abstract][Full Text] [Related]
80. Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Goossens GH; Jocken JW; Blaak EE; Schiffers PM; Saris WH; van Baak MA Hypertension; 2007 Mar; 49(3):542-7. PubMed ID: 17224474 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]